We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Enabled Chest X-Ray Solution Identifies Heart Failure Risk

By MedImaging International staff writers
Posted on 02 Oct 2023
Image: The qXR-CTR chest X-ray solution has received FDA clearance as a potential indicator for identifying heart failure risk (Photo courtesy of Qure.ai)
Image: The qXR-CTR chest X-ray solution has received FDA clearance as a potential indicator for identifying heart failure risk (Photo courtesy of Qure.ai)

Heart failure is often a difficult condition to diagnose correctly because its symptoms can be quite vague. Now, a novel chest X-ray algorithm can screen for telltale signs of heart failure, such as an enlarged cardiothoracic ratio (CTR) and fluid in the lungs, along with other indicators visible on X-rays. This development represents a significant leap forward in the fields of medical imaging and heart care, offering a new method for early detection of heart failure via automated analysis of chest X-rays.

The qXR-CTR artificial intelligence (AI)-enabled chest X-ray solution from Qure.ai Technologies (New York, NY, USA) is an AI-powered solution designed to assist doctors in both hospital and clinic settings by automating the measurement of the CTR on chest X-rays. Specifically, it calculates the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity, providing the most accurate indicator of cardiomegaly on plain film. By employing advanced AI algorithms, the technology offers quick and accurate results, saving valuable time for healthcare professionals and enhancing the reliability of diagnoses.

Qure.ai has now received FDA clearance for measuring the CTR utilizing qXR-CTR, marking the company's 12th FDA-cleared algorithm. Qure.ai’s previous FDA-cleared findings include endotracheal tube location, tracheostomy tube location, pneumothorax, and pleural effusion identification for CXR; qER for intracranial hemorrhage detection on head CT scans, and qER Quant for quantifying serious abnormalities on head CT scans.

"We are delighted to receive FDA clearance for qXR-CTR,” said Prashant Warier, Co-Founder and CEO at Qure.ai. “This cutting-edge algorithm enhances the accuracy and efficiency of CTR assessment and empowers healthcare professionals with a valuable tool to diagnose and monitor risk of heart failure. This achievement reaches an industry record for the greatest number of FDA-cleared findings on CXR scans, demonstrating Qure.ai's commitment to advancing better patient outcomes through AI-driven solutions."

Related Links:
Qure.ai Technologies

Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Ultrasound Needle Guidance System
SonoSite L25
Ultrasound Table
Women’s Ultrasound EA Table

Channels

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.